Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€2.68

€2.68

-3.600%
-0.1
-3.600%
€9.00

€9.00

 
16:15 / Tradegate WKN: A0HGQF / Name: MagForce / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
15.12.21
-5.92%
€9.00
24.02.21
-41.56%
buy
Your prediction

MagForce AG Stock

Heavy losses for MagForce AG today as the stock fell by -€0.100 (-3.600%).
With 1 Sell predictions and 1 Buy predictions the community sentiment towards the MagForce AG stock is not clear.
With a target price of €9.00 there is potential for a 235.821% increase which would mean more than doubling the current price of €2.68 for MagForce AG.
Our community identified positive and negative aspects for MagForce AG stock for the coming years. 1 users see the criterium "Business model" as a plus for the MagForce AG stock. On the other hand our users think that "General Risks" could be a problem in the future.

Pros and Cons of MagForce AG in the next few years

Pros
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of MagForce AG vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
MagForce AG -3.600% -1.418% -0.714% -41.841% 2.206% -51.736% -35.974%
Paion AG -3.000% -9.690% 14.029% -43.171% 15.728% -38.414% -48.641%
B.R.A.I.N. Biotechnology Research and Information Network AG -2.900% -3.213% 6.637% 6.874% 6.167% -22.006% -53.654%
Formycon AG -2.990% 1.829% -8.743% -21.473% -14.065% 81.851% 86.391%

Other discussions about MagForce AG Stock

New thread Forum

News

DGAP-News: MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval
DGAP-News: MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval